Surgical & Examination Gloves Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Regulatory and licence map for this surgical examination gloves plant project

The regulatory architecture for medical gloves in India operates across three tiers: the Drugs and Cosmetics Act for CDSCO licensing, the Bureau of Indian Standards for product certification, and environmental and labour statutes for factory establishment. Unlike pharmaceutical formulations, gloves follow a device regulatory pathway post the Medical Devices Rules, 2017 amendment, which classified examination and surgical gloves as Class A or B devices depending on risk profile. A coherent approval sequencing, from factory site selection through CDSCO license and BIS certification, is a critical path item on the project schedule.

• CDSCO Medical Device License under Medical Devices Rules, 2017: Examination gloves classified as Class A (low risk) and surgical gloves as Class B (moderate risk); Form MD-3 for import license, MD-9 for manufacturing license; CDSCO portal registration with state licensing authority (SLA) intimation; US FDA 510(k) clearance required for US export market entry, with predicate device reference and biocompatibility testing per ISO 10993 series.
• BIS Product Certification under IS 13450 (Parts 1-8): IS 13450:2022 aligns with ISO 11193 for examination gloves and IS 7178 for surgical gloves; Bureau of Indian Standards licensing with permit scheme for large-volume manufacturers; mandatory ISI mark for domestic institutional sales and government procurement; quarterly surveillance testing from BIS-empanelled laboratories.
• Schedule M compliance under Drugs and Cosmetics Rules, 1945: Manufacturing facility must meet Schedule M requirements for medical devices including cleanroom specifications (ISO Class 7-8 for glove production areas), equipment qualification, and process validation protocols; CDSCO inspection before license grant with re-inspection every 3 years.
• EIA Notification 2006 (as amended 2024): Greenfield glove manufacturing with latex processing triggers environmental clearance if plant area exceeds 20,000 sq. metres or if effluent discharge exceeds 50 kilolitres per day; Consent to Establish (CTE) and Consent to Operate (CTO) required under Water (Prevention and Control of Pollution) Act, 1974 and Air (Prevention and Control of Pollution) Act, 1981 from respective State Pollution Control Board.
• GST Registration and GST Returns: Medical gloves attract 12% GST under HSN 4015 (rubber gloves) or HSN 4014 (rubber surgical gloves); GSTN registration mandatory; input tax credit avancement on capital goods and raw materials; Composition scheme not available for manufacturers above ₹1 crore turnover.
• EPF and ESI Registration: All factories employing 20 or more persons must register under the Employees' Provident Funds and Miscellaneous Provisions Act, 1952 (EPF) and Employees' State Insurance Act, 1948 (ESI); factory gate-cost includes employer contribution of 12% (EPF) and 3.25% (ESI) on gross wages; compliance reporting quarterly to EPFO portal.
• Factory License under Factories Act, 1948: State Factory Directorate licensing with approved plant layout, occupational health provisions, and hazardous process notification for latex-dipping operations; renewal every 5 years with biennial safety audit.
• Export Licensing and Free Trade Agreements: Import-Export Code (IEC) mandatory via DGFT portal; US FDA establishment registration for exporters; CE marking under EU Medical Device Regulation 2017/745 for European market access; anti-dumping duty considerations on nitrile butadiene rubber (NBR) imports from China, South Korea, and Thailand.
• MCA SPICe+ Company Registration: Single-window company incorporation with DIN, PAN, TAN, GST registration, EPFO, and ESIC through the MCA SPICe+ form; llpIn case of LLP structure, Form FiLLiP filing with registrar of companies (ROC); minimum 2 designated partners required.

KAMRIT Financial Services LLP manages the complete regulatory filing sequence from MCA SPICe+ incorporation through CDSCO manufacturing license, BIS certification, and pollution control board consents, coordinating with state-level empaneled facilitators across Gujarat, Maharashtra, and Tamil Nadu for in-person follow-up. Our DPR deliverable includes a pre-populated compliance calendar, CDSCO Form MD-9 draft, BIS application file, and EIA consultation brief, reducing the applicants regulatory timeline to 8-14 months on a fast-track basis.

Sectoral context for this surgical & examination gloves plant project

The surgical and examination gloves market is a subset of the larger medical devices industry, distinct from pharmaceuticals, medical electronics, and hospital consumables in its regulatory pathway, raw material dependencies, and buyer procurement behaviour. Within the gloves category, three sub-segments carry meaningfully different growth trajectories. Examination-grade nitrile gloves are the fastest-growing, expanding at an estimated 16-18% CAGR, driven by infection-control awareness post-COVID and government mandates for single-use PPE in public healthcare facilities.

Examination-grade latex gloves are growing at 8-10% CAGR, facing substitution pressure from nitrile in institutional channels but retaining share in cost-sensitive primary healthcare and rural markets. Surgical gloves, regulated as Class A medical devices by CDSCO, are the smallest but highest-margin segment, growing at 6-8% CAGR with procurement dominated by large hospital chains and state government rate contracts. The export sub-segment is bifurcated: low-cost latex examination gloves compete with Southeast Asian producers on price for US and EU retail channels, while premium nitrile surgical gloves require US FDA 510(k) clearance or CE marking for meaningful volume.

Domestically, hospital tender cycles average 12-18 months with annual rate contracts from NHSRC-approved suppliers. The private retail channel, including pharmacy chains and diagnostics chains, operates on shorter procurement cycles with higher per-unit margins. Industrial safety gloves, though sometimes manufactured on shared equipment, represent a separate product category with different standards (IS 12233) and distribution channels, and are excluded from this DPR's scope.

Project-specific demand drivers

• Hospital demand
• Export to US / EU
• Latex / nitrile mix
• PLI Medical Devices

Technology and machinery benchmarks

Glove manufacturing technology splits broadly between the dipped-latex process and the nitrile compounding and dipping process, each with distinct capital intensity, conversion costs, and product quality outcomes. The latex-dipping line involves clay or ceramic formers passing through successive latex baths, with leaching, chlorination, and polymer coating stages, before automated stripping and packaging. The nitrile line follows a similar dipped-process route but substitutes a nitrile butadiene rubber (NBR) latex compound, requiring precision in compound viscosity control and curing oven temperature profiling.

Key equipment suppliers in the Indian market include Rexello and indigenized Chinese lines from Shandong Yuyuan and YGCM, offering competitive pricing at ₹4-8 crore per 100-million-pieces-per-annum line. European equipment from R. A.

Jones (US) and IGP Starke (Germany) commands a 40-60% premium but delivers superior gauge consistency and lower reject rates. For a ₹25-45 crore CapEx facility targeting 150-250 million pieces per annum, a 2-line setup with one latex and one nitrile line represents an optimal risk-weighted capital deployment, achieving a blended capacity utilization of 70% by Year 2 and reaching 85-90% by Year 4. Energy consumption benchmarks at 2.5-3.5 kWh per 1,000 pieces for nitrile lines and 1.8-2.5 kWh per 1,000 pieces for latex lines, with natural gas or PNG as the preferred heat source for curing ovens.

Water consumption, critical for leaching and washing stages, ranges from 8-12 kilolitres per million pieces, necessitating a zero-liquid discharge (ZLD) system with membrane bioreactor and RO concentrate evaporator, adding ₹2-4 crore to the project cost. The conversion cost per piece, including raw material, labour, energy, and overhead, ranges from ₹1.80 to ₹3.20 per piece for examination-grade nitrile and ₹1.20 to ₹2.20 per piece for latex, with raw material (NBR latex and natural rubber latex) representing 55-65% of total conversion cost. Top Glove India's integrated backward supply chain, including its own latex plantations and NBR supply agreements, illustrates the cost advantage available at scale, which smaller domestic entrants partially offset through leaner overhead structures and proximity to domestic institutional buyers.

VRG Khoor's focus on chlorination-processed latex gloves for the EU market demonstrates that European buyers will accept 15-20% higher pricing for consistent pinhole-free quality, justifying investment in premium quality-control equipment including automated visual inspection systems priced at ₹80-120 lakh per line.

Bankable Means of Finance for this surgical examination gloves plant project

For a surgical examination gloves plant project at ₹15 crore - ₹100 crore CapEx with a 4 - 6-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 30-40% promoter equity and 60-70% debt. The primary lender pool for this scale is SBI MSME, Bank of Baroda, HDFC Bank, ICICI Bank, Axis Bank term loans plus working capital facilities. The applicable overlay schemes that materially compress effective cost-of-capital are CGTMSE up to ₹5 cr, PLI sector overlay where eligible, state capital subsidy. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

Risks and mitigation for this project

For surgical examination gloves plant at ₹15 crore - ₹100 crore CapEx and 4 - 6-year payback, the three risks KAMRIT structures mitigation around are demand-side execution risk, input-cost volatility, and regulatory-delay risk. For this category specifically, KAMRIT also models supplier concentration risk, currency exposure where input-imports exceed 25 percent of CapEx, and the working-capital cycle stretch in the first 18 months of commissioning. The Bankable DPR contains the full three-scenario sensitivity (base / bull / bear) on revenue, gross margin, and CapEx that a credit committee needs to see.

How to engage with KAMRIT on this report

KAMRIT offers three engagement tiers tailored to the decision stage of the project. Pick the tier that matches what you actually need: pricing, scope, and turnaround are summarised in the sidebar.

City-specific versions of this report